Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours

Margalit, Ofer; Shacham‐Shmueli, Einat; Itay, Amit; Berger, Raanan; Halperin, Sharon; Jurkowicz, Menucha; Sapir, Einav; Olmer, Liraz; Regev‐Yochay, Gili; Lustig, Yaniv; Rahav, Galia

doi:10.1016/j.ejca.2022.03.013

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study [ 31 ], the overall immune response was limited in individuals aged > 55 years following two doses of the inactivated CoronaVac vaccine. Intriguingly, a clinical trial of the mRNA-1273 COVID-19 vaccine found comparable immunological responses in older and younger individuals [ 32 ], while the ChAdOx1nCoV-19 vaccine induced comparable immune responses in younger and older patients [ 33 , 34 ]. However, empirical data are required to evaluate the potential link between age and Ab responses to inactivated COVID-19 vaccines, as age may be not related to Ab responses.…”

Section: Discussionmentioning

confidence: 99%

“…Student's t-test (confidence interval, CI)/Mann-Whitney U test (interquartile range, IQR) were used for two-group comparison (healthy controls and OPTB patients). The p-values represented in this figure are all adjusted p-values of the mRNA-1273 COVID-19 vaccine found comparable immunological responses in older and younger individuals[32], while the ChAdOx1nCoV-19 vaccine induced comparable immune responses in younger and older patients[33,34]. However, empirical data are required to evaluate the potential link between age and Ab responses to inactivated COVID-19 vaccines, as age may be not related to Ab responses.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

Yang

Feng

Wang

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The immunogenicity and safety of vaccines against coronavirus disease 2019 (COVID-19) remain unknown in patients with a history of pulmonary tuberculosis (OPTB). Therefore, the safety and effectiveness of inactivated vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were assessed in patients with a history of PTB. The study cohort included 106 healthy controls and 93 adult patients with OPTB who received a two-dose vaccination. The study period was 21 to 105 days. Concentrations of antibodies (Abs) against receptor-binding domain (RBD) IgG and SARS-CoV-2 neutralizing Abs (NAbs) were measured, in addition to the frequencies of SARS-CoV-2-specific B and a portion T cells. The incidence of adverse events was similar between the OPTB patients and healthy controls. No severe adverse events occurred. Concentrations of Abs against RBD-IgG and CoV-2 neutralizing Abs in addition to the frequencies of RBD-specific memory B cells proportions were lower in OPTB patients than the healthy controls (all, p < 0.05), while the frequencies of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4 + ) cells were higher ( p = 0.023). There was no obvious correlation between age and blood concentrations of Abs against RBD-IgG and CoV-2 neutralizing Abs, while immune responses were similar in the fibrosis and calcification groups. The period of time following full-course vaccination and lymphocyte counts were associated to anti-RBD-IgG responses. Inactivated COVID-19 vaccinations were well tolerated in OPTB patients, although immunogenicity was limited in this population. This study has been registered at ClinicalTrials.gov (NCT05043246). Supplementary Information The online version contains supplementary material available at 10.1007/s10096-023-04566-0.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

Yang

Feng

Wang

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Although patients with cancer have not been part of initial clinical trials, the clinical efficacy of vaccination against COVID-19 has now been proven for this population as well. 35 While the rate of seroconversion as well as absolute antibody levels seem to be lower in cancer patients compared to the healthy individuals, 36 , 37 overall, a clinical efficacy with an 80-90% prevention rate of symptomatic COVID-19 can be expected in patients with cancer. 38 However, cancer patients remain at an increased risk of severe disease despite vaccination compared to the general population 39 , 40 and thus several aspects need to be taken into account: Patients with cancer are often of advanced age and harbor co-morbidities, that may lead to reduced vaccine efficacy 38 Patients with cancer in general seem to exhibit a more rapidly waning immunity than the general population which requires more frequent and earlier booster doses than the general population 35 , 41 , 42 Patients with cancer are often undergoing therapy with immunosuppressive drugs which reduce the immune response to vaccines.…”

Section: Vaccinationmentioning

confidence: 99%

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

Giesen¹,

Busch²,

Schalk³

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

“…When comparing patients with solid malignancies to healthy controls, median neutralizing antibody titers were found to be similar between solid cancer patients and controls ( p = 0.566), indicating comparable protection in seropositive people who mounted an immune response to vaccination [ 11 ]. On the other hand, a study conducted by Massarweh et al, found that patients with primary brain tumors had an 88.2% seroconversion rate following the Pfizer vaccine, though these patients demonstrated significantly lower IgG titers than controls ( p = 0.002) [ 12 ].…”

Section: Immunogenicity Of the Covid-19 Vaccines In Solid And Hematol...mentioning

confidence: 99%

Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges

Almasri

Bshesh

Khan

et al. 2022

Cancers

View full text Add to dashboard Cite

Few guidelines exist for COVID-19 vaccination amongst cancer patients, fostering uncertainty regarding the immunogenicity, safety, and effects of cancer therapies on vaccination, which this review aims to address. A literature review was conducted to include the latest articles covering the immunogenicity and safety of COVID-19 vaccination in patients with solid and hematologic cancers receiving various treatments. Lower seropositivity following vaccination was associated with malignancy (compared to the general population), and hematologic malignancy (compared to solid cancers). Patients receiving active cancer therapy (unspecified), chemotherapy, radiotherapy, and immunosuppressants generally demonstrated lower seropositivity compared to healthy controls; though checkpoint inhibition, endocrine therapy, and cyclin dependent kinase inhibition did not appear to affect seropositivity. Vaccination appeared safe and well-tolerated in patients with current or past cancer and those undergoing treatment. Adverse events were comparable to the general population, but inflammatory lymphadenopathy following vaccination was commonly reported and may be mistaken for malignant etiology. Additionally, radiation recall phenomenon was sporadically reported in patients who had received radiotherapy. Overall, while seropositivity rates were decreased, cancer patients showed capacity to generate safe and effective immune responses to COVID-19 vaccination, thus vaccination should be encouraged and hesitancy should be addressed in this population.

show abstract

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours

Cited by 6 publications

References 24 publications

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges

Contact Info

Product

Resources

About